Hospira

2Q Revenues: $671 million (+1%)

2Q Earnings: $54 million (-25%)

YTD Revenues: $1.3 billion (+1%)

YTD Earnings: $134 million (-10%)

Comments: R&D expense rose 19% percent in the quarter to $39 million. S,G&A expense in the quarter was $111 million, or 17% of sales, compared with $87 million, or 13% of sales in 2Q2005. The company completed its legal separation from Abbott in the quarter, including the transition of the remaining countries to Hospira.